Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

被引:106
作者
Preaud, Emmanuelle [1 ]
Durand, Laure [2 ]
Macabeo, Berengere [2 ]
Farkas, Norbert [3 ]
Sloesen, Brigitte [4 ]
Palache, Abraham [5 ]
Shupo, Francis [6 ]
Samson, Sandrine I. [1 ]
机构
[1] Sanofi Pasteur MSD, F-69367 Lyon, France
[2] Sanofi Pasteur, F-69007 Lyon, France
[3] Novartis Vaccines & Diagnost AG, CH-4056 Basel, Switzerland
[4] GlaxoSmithKline, Rixensart, Belgium
[5] Abbott, NL-1381 CP Weesp, Netherlands
[6] Creativ Ceut Ltd, London SE1 9QQ, England
关键词
Influenza; Public health policy; Vaccines and immunization; Modeling; Epidemiology; COST-EFFECTIVENESS; EXCESS MORTALITY; ENGLAND; BURDEN; NORWAY; IMPACT; UNION;
D O I
10.1186/1471-2458-14-813
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels. Methods: A model was generated to assess the annual public health benefits and economic importance of influenza vaccination in 5 WHO recommended vaccination target groups (children 6 - 23 months of age; persons with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age) in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative assumptions, age-based and country-specific data. Results: Out of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80 million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the 75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27 countries, average annual influenza-related events averted would increase from current levels to an additional +1.6 to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would increase by an additional +(sic)190 to +(sic)226 million yearly, in vaccination target groups. Conclusions: Full implementation of current influenza vaccination recommendations of 75% vaccination coverage rate (VCR) in Europe by the 2014-2015 influenza season could immediately reduce an important public health and economic burden.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic
    Jaime L Rubin
    Lisa J McGarry
    Keith P Klugman
    David R Strutton
    Kristen E Gilmore
    Milton C Weinstein
    BMC Infectious Diseases, 10
  • [22] Vaccination of Healthy Children Against Seasonal Influenza A European Perspective
    Heikkinen, Terho
    Tsolia, Maria
    Finn, Adam
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (08) : 881 - 888
  • [23] Exploring the potential public health benefits of universal influenza vaccine
    DePasse, Jay, V
    Nowalk, Mary Patricia
    Smith, Kenneth J.
    Raviotta, Jonathan M.
    Shim, Eunha
    Zimmerman, Richard K.
    Brown, Shawn T.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (12) : 2919 - 2926
  • [24] Seasonal Influenza Vaccination and Recommendation: The Difference between General Practitioners and Public Health Workers in China
    Rong, Hongguo
    Lai, Xiaozhen
    Ma, Xiaochen
    Hou, Zhiyuan
    Li, Shunping
    Jing, Rize
    Zhang, Haijun
    Peng, Zhibin
    Feng, Luzhao
    Fang, Hai
    VACCINES, 2020, 8 (02)
  • [25] Economic Value of Seasonal and Pandemic Influenza Vaccination during Pregnancy
    Beigi, Richard H.
    Wiringa, Ann E.
    Bailey, Rachel R.
    Assi, Tina-Marie
    Lee, Bruce Y.
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (12) : 1784 - 1792
  • [26] Ancillary benefits of seasonal influenza vaccination in middle-income countries
    Ebama, Malembe S.
    Chu, Susan Y.
    Azziz-Baumgartner, Eduardo
    Lafond, Kathryn E.
    McCarron, Margaret
    Hadler, Stephen C.
    Porter, Rachael M.
    McKinlay, Mark
    Bresee, Joseph
    VACCINE, 2021, 39 (14) : 1892 - 1896
  • [27] Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices
    Salleras, L.
    Navas, E.
    Dominguez, A.
    Ibanez, D.
    Prat, A.
    Garrido, P.
    Asenjo, M. A.
    Torner, N.
    VACCINE, 2009, 27 (25-26) : 3454 - 3458
  • [28] The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China
    Caldwell, Ronald
    Roberts, Craig S.
    An, Zhijie
    Chen, Chieh-, I
    Wang, Bruce
    BMC INFECTIOUS DISEASES, 2015, 15
  • [29] Using the health belief model to identify barriers to seasonal influenza vaccination among Australian adults in 2019
    Trent, Mallory J.
    Salmon, Daniel A.
    MacIntyre, C. Raina
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2021, 15 (05) : 678 - 687
  • [30] The Health and Economic Benefits of Influenza Vaccination for Healthy and At-Risk Persons Aged 65 to 74 Years
    Kristin L. Nichol
    Michael Goodman
    PharmacoEconomics, 1999, 16 : 63 - 71